Self-Monitoring Blood Glucose Market Size and Share

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Compare market size and growth of Self-Monitoring Blood Glucose Market with other markets in Healthcare Industry

Self-Monitoring Blood Glucose Market Analysis by Mordor Intelligence

The Self-Monitoring Blood Glucose market size is USD 15.47 billion in 2025 and is forecast to reach USD 20.92 billion by 2030, reflecting a 6.23% CAGR during the period. Robust demand stems from the sharp rise in diabetes prevalence, continuing migration toward home-based management, and rapid adoption of digitally connected meters that relay readings to smartphones and cloud portals for data-driven care. Price competition in test strips remains intense, yet recurring strip consumption still anchors revenue. Suppliers are differentiating through eco-friendly materials, longer-life sensors, and Bluetooth-enabled devices that fit seamlessly into tele-diabetes workflows. North America retains leadership owing to broad reimbursement coverage, while Asia-Pacific delivers the fastest unit growth as rising incomes intersect with expanding insurance schemes.

Key Report Takeaways

  • By product type, test strips led with 76.7% revenue share in 2024, whereas glucose meters are projected to accelerate at a 11.3% CAGR through 2030.
  • By technology, electrochemical sensors captured 90% of Self-Monitoring Blood Glucose market share in 2024, while photometric platforms are forecast to grow 9.8% annually to 2030.
  • By modality, hand-held conventional meters held 87% of volume in 2024; the wearable/connected segment is advancing at the same 13.85% CAGR to 2030.
  • By application, type 2 diabetes commanded 80% of the Self-Monitoring Blood Glucose market size in 2024 and the pre-diabetes screening segment is poised for a 10.5% CAGR between 2025-2030.
  • By end user, home-care settings accounted for 61% share in 2024, while ambulatory surgical centers record the highest projected 9.3% CAGR through 2030.
  • By distribution channel, retail pharmacies captured 44.0% of market share in 2024 and online pharmacies is rising at an 13.4% CAGR through 2030.
  • By geography, North America represented 39.9% of global revenue in 2024; Asia-Pacific is set to surge at 9.5% CAGR to 2030.

Segment Analysis

By Product Type: Test Strips Anchor Recurring Revenue

Test strips generated 76.7% of Self-Monitoring Blood Glucose market revenue in 2024, propelled by the necessity for multiple daily measurements among insulin users. This consumable model insulates suppliers from hardware replacement cycles, though commoditization has narrowed unit margins. Strip innovations now target capillary volumes below 0.4 µL and 5-second read times to boost adherence. The Self-Monitoring Blood Glucose market size tied to glucose meters is expanding swiftly which deliver 11.3% forecast CAGR through 2030, offering richer data and value-added services that justify premiums. Manufacturers partner with smartphone-app developers to merge nutrition logs, step counts, and medication reminders, enhancing differentiation. Efforts to minimize strip environmental footprint—bioplastic housings and corrugated paper packaging—address rising consumer sustainability expectations.

Second-generation strips incorporate multi-electrode designs that cross-check hematocrit and ambient temperature, cutting user error. Suppliers bundle loyalty programs that discount bulk packs, locking patients into proprietary ecosystems. Conversely, healthcare systems in lower-income regions still prioritize affordability over connectivity, sustaining basic strip demand even as unit prices slip.

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By Technology: Electrochemical Sensors Retain Primacy

Electrochemical sensors underpin 90% of devices sold, testament to decades of reliability and cost efficiency. Their enzyme-mediated current output correlates linearly with glucose concentration, simplifying calibration. Continued miniaturization using carbon-nanotube electrodes enables thinner, shorter strips that require less blood. Photometric methods hold only a modest share today yet post the highest growth trajectory at 9.8% owing to optical chips that promise non-enzymatic detection and potential sweat-based applications. The Self-Monitoring Blood Glucose market share advantage of electrochemical platforms remains secure until optical accuracy and unit economics converge.

Researchers are experimenting with surface-enhanced Raman spectroscopy to resolve interstitial glucose yet face challenges such as skin-tone variability and signal-to-noise. Hybrid meters that incorporate both electrochemical and photometric modules are emerging, offering redundancy and facilitating transition paths for users. Regulatory agencies mandate tight mean absolute relative difference thresholds; thus, new technologies must surpass electrochemical benchmarks to gain clinical legitimacy.

By Modality: Connected Devices Re-Envision User Experience

Hand-held conventional meters delivered 87% of units in 2024, favored for low entry price and simple workflow. However, connected wearables—arm-band or wrist-strap format—are expected to post a 13.85% CAGR as younger cohorts seek seamless health dashboards. The Self-Monitoring Blood Glucose market size attributable to connected modalities will grow as cloud-sync subscriptions and coaching packages unlock recurring revenue streams. Hardware advances such as low-energy Bluetooth, NFC tap-upload, and color touchscreens are enhancing convenience.

Legacy meters remain indispensable where cellular coverage or smartphone ownership is limited. Manufacturers offer hybrid kits bundling a basic reader with upgrade coupons for connected models, nurturing step-up migration. Hospitals value connected devices for auto-charting capabilities that cut nursing documentation time by up to 30%, aligning with electronic medication administration records.

By Application: Type 2 Diabetes Commands Volume

Type 2 diabetes patients accounted for 80% of Self-Monitoring Blood Glucose market demand in 2024, yet individual testing frequency ranges widely depending on therapy intensity. Insulin-treated type 2 segments test nearly as often as type 1 counterparts, whereas diet-controlled cohorts may monitor only weekly. Structured testing protocols promoted by professional societies are lifting strip volumes even in non-insulin users. The Self-Monitoring Blood Glucose market size linked to pre-diabetes screening—especially among weight-loss program participants—records the fastest 10.5% CAGR as employers subsidize metabolic wellness benefits.

Type 1 diabetes, though smaller in patient numbers, generates high device turnover due to obligatory insulin dosing decisions. Product design is increasingly sensitive to pediatric needs, adding animated feedback and voice prompts. Gestational diabetes monitoring demand is growing with rising maternal age and obesity; disposable lancets with integrated needles address infection-control requirements in obstetric settings.

Self-Monitoring Blood Glucose Market: Market Share by Application
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By End User: Home-Care Leads, Ambulatory Centers Rise

Home users generated 61% of revenue in 2024, underscoring the shift to patient-empowered management. Digital literacy gains and remote coaching programs reinforce adherence. Hospitals and clinics remain important, particularly for perioperative glucose control; consensus guidelines endorse hourly checks for certain inpatients, supporting premium strip variants validated for critical care. Ambulatory surgery centers show 9.3% CAGR as same-day procedures proliferate, necessitating rapid-turnaround glucose verification.

Pharmacists increasingly act as device educators, yet surveys reveal average didactic time on glucose monitoring is under 60 minutes during doctorate curricula, prompting calls for expanded training. Telepharmacy models now deliver virtual onboarding sessions, boosting rural patient access. Diagnostic laboratories leverage high-throughput strip analyzers for point-of-care outreach programs, widening community screening.

By Distribution Channel: Retail Pharmacies Maintain First Position

Retail pharmacies captured 44% of sales in 2024, capitalizing on walk-in convenience and the ability to bill insurance plans in real time. Chain operators stock private-label strips priced 20–30% below brands, pressuring incumbents. Hospital pharmacies supply meters for inpatient use and dispense starter kits at discharge to support continuity of care. Online pharmacies, while only mid-teens share today, are expanding at 13.4% CAGR as free two-day shipping and automatic refill services resonate with tech-savvy users.

Manufacturers run direct-to-consumer web stores that bundle supplies with tele-coaching, bypassing wholesale mark-ups. Subscription models ship strips monthly, smoothing cash flow and improving adherence. Regulatory clarity around e-prescriptions in multiple U.S. states has accelerated digital pharmacy adoption, enabling frictionless device provisioning under payer formularies.

Geography Analysis

North America accounted for 39.9% of 2024 revenue, anchored by the United States where diabetes prevalence stood at 11.3% of adults and healthcare spend per capita remains the world’s highest. Medicare and private insurers reimburse both meter hardware and supplies, sustaining sizeable Self-Monitoring Blood Glucose market share and funding next-generation connected devices. Canada mirrors these dynamics, although provincial formularies emphasize price caps on strips, spurring growth of lower-cost brands. Widespread 4G/5G coverage underpins tele-diabetes platforms that integrate meter feeds directly into electronic health records.

Europe ranks second, with Germany alone holding more than one quarter of regional revenue in 2024. Statutory insurance schemes reimburse unlimited strips for insulin users, driving volumes despite fierce tender-led price erosion. Environmental directives such as the European Green Deal elevate scrutiny of single-use plastic components, prompting suppliers to introduce recyclable cartridges and take-back pilots. Nations like Sweden and France have begun factoring carbon-footprint metrics into procurement scoring, offering early-mover advantages to eco-forward brands.

Asia-Pacific is the fastest-growing region at 9.5% CAGR through 2030. China’s adult diabetes prevalence of 10.9% translates into more than 140 million potential users; domestic manufacturers leverage scale to supply low-priced strips, while foreign brands compete on accuracy and connectivity. India’s expanding middle class and government health insurance schemes such as Ayushman Bharat widen access, yet rural distribution gaps persist. Smartphone penetration exceeding 70% across urban Southeast Asia accelerates adoption of app-linked meters. Local language interfaces and cloud servers hosted within national borders address regulatory and cultural preferences, facilitating uptake.

Self-Monitoring Blood Glucose Market CAGR (%), Growth Rate by Region
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Competitive Landscape

The Self-Monitoring Blood Glucose market is moderately concentrated, with the top five manufacturers accounting significant global revenue. Abbott, Roche, and LifeScan remain dominant based on broad strip portfolios, proprietary enzyme technologies, and global sales footprints. Abbott strengthened ecosystem stickiness in 2025 by integrating its LibreView platform with multiple telehealth providers, enabling one-click data sharing that anchors device selection. Roche advanced sustainability credentials by moving to paper-based test-strip vials that cut plastic by 45%.

Emerging challengers focus on connected value propositions. Ascensia’s 2024 FDA-cleared CONTOUR PLUS BLUE meter pairs via Bluetooth to its app, pushing personalized insights and weekly glycemic reports. Start-ups are trialing optical micro-sensors embedded in smartwatch straps, though most remain in investigational stages. Contract manufacturing in Malaysia and Mexico expands capacity while trimming lead times for regional supply.

Strategic alliances proliferate. Device firms partner with insulin-delivery companies to offer integrated dosing calculators, raising competitive barriers. Vertical integration trends include enzyme production acquisitions and strip-printing technology licensing, aiming to offset price compression. Intellectual-property litigation persists over electrode coatings and data-format protocols, yet cross-licensing deals are emerging as companies prioritize platform interoperability to satisfy payer requirements for open data sharing.

Self-Monitoring Blood Glucose Industry Leaders

  1. F. Hoffmann-La Roche AG

  2. Ascensia Diabetes Care

  3. LifeScan Inc.

  4. ARKRAY Inc.

  5. Abbott Laboratories

  6. *Disclaimer: Major Players sorted in no particular order
Self-monitoring Blood Glucose Market Concentration
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Need More Details on Market Players and Competitors?
Download PDF

Recent Industry Developments

  • March 2025: Novo Nordisk launched the ReMed plastic take-back program to collect used diabetes-device components, advancing its goal of zero environmental impact by 2030.
  • February 2024: Ascensia Diabetes Care received FDA clearance for the CONTOUR PLUS BLUE Blood Glucose Monitoring System featuring Bluetooth connectivity to smartphones and tablets.

Table of Contents for Self-Monitoring Blood Glucose Industry Report

1. Introduction

  • 1.1 Study Assumptions & Market Definition
  • 1.2 Scope of the Study

2. Research Methodology

3. Executive Summary

4. Market Landscape

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Escalating Global Diabetes Prevalence And Earlier Diagnostic Rates
    • 4.2.2 Shift Toward Home-Based, Patient-Empowered Glucose Management
    • 4.2.3 Expanding Third-Party Reimbursement And Insurance Coverage For SMBG Supplies Across Major Economies
    • 4.2.4 Rising Disposable Income And Diabetes Awareness In High-Growth Emerging Markets
    • 4.2.5 Integration Of SMBG Data With Digital Health & Tele-Diabetes Platforms Driving Value-Added Services
  • 4.3 Market Restraints
    • 4.3.1 Intensifying Price Competition And Commoditization Of Test Strips Compressing Margins
    • 4.3.2 Stringent Regulatory & Quality-Compliance Requirements Prolonging Product Approval Timelines
    • 4.3.3 Environmental And Waste-Management Concerns Over Single-Use Strips And Lancets
  • 4.4 Supply-Chain Analysis
  • 4.5 Technological Outlook
  • 4.6 Porter's Five Forces
    • 4.6.1 Bargaining Power of Suppliers
    • 4.6.2 Bargaining Power of Buyers
    • 4.6.3 Threat of New Entrants
    • 4.6.4 Threat of Substitutes
    • 4.6.5 Competitive Rivalry

5. Market Size & Growth Forecasts (Value, USD)

  • 5.1 By Product Type
    • 5.1.1 Glucose Meters
    • 5.1.2 Test Strips
    • 5.1.3 Lancets
  • 5.2 By Technology
    • 5.2.1 Electrochemical
    • 5.2.2 Photometric
  • 5.3 By Modality
    • 5.3.1 Hand-held Conventional
    • 5.3.2 Wearable / Connected
  • 5.4 By Application
    • 5.4.1 Type 1 Diabetes
    • 5.4.2 Type 2 Diabetes
    • 5.4.3 Gestational Diabetes
    • 5.4.4 Prediabetes
  • 5.5 By End-user
    • 5.5.1 Hospitals & Clinics
    • 5.5.2 Home-care Settings
    • 5.5.3 Diagnostic Laboratories
    • 5.5.4 Ambulatory Surgical Centers
  • 5.6 By Distribution Channel
    • 5.6.1 Retail Pharmacies
    • 5.6.2 Hospital Pharmacies
    • 5.6.3 Online Pharmacies
    • 5.6.4 Others
  • 5.7 Geography
    • 5.7.1 North America
    • 5.7.1.1 United States
    • 5.7.1.2 Canada
    • 5.7.1.3 Mexico
    • 5.7.2 Europe
    • 5.7.2.1 Germany
    • 5.7.2.2 United Kingdom
    • 5.7.2.3 France
    • 5.7.2.4 Italy
    • 5.7.2.5 Spain
    • 5.7.2.6 Rest of Europe
    • 5.7.3 Asia-Pacific
    • 5.7.3.1 China
    • 5.7.3.2 Japan
    • 5.7.3.3 India
    • 5.7.3.4 Australia
    • 5.7.3.5 South Korea
    • 5.7.3.6 Rest of Asia-Pacific
    • 5.7.4 Middle East and Africa
    • 5.7.4.1 GCC
    • 5.7.4.2 South Africa
    • 5.7.4.3 Rest of Middle East and Africa
    • 5.7.5 South America
    • 5.7.5.1 Brazil
    • 5.7.5.2 Argentina
    • 5.7.5.3 Rest of South America

6. Competitive Landscape

  • 6.1 Market Concentration
  • 6.2 Market Share Analysis
  • 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Business Segments, Financials, Headcount, Key Information, Market Rank, Market Share, Products and Services, and analysis of Recent Developments)
    • 6.3.1 Abbott Laboratories
    • 6.3.2 F. Hoffmann-La Roche AG
    • 6.3.3 LifeScan Inc.
    • 6.3.4 Ascensia Diabetes Care
    • 6.3.5 ARKRAY Inc.
    • 6.3.6 Terumo Corp.
    • 6.3.7 i-SENS Inc.
    • 6.3.8 Nova Biomedical
    • 6.3.9 Bionime Corporation
    • 6.3.10 AgaMatrix Inc.
    • 6.3.11 ACON Laboratories
    • 6.3.12 Trividia Health
    • 6.3.13 Rossmax International
    • 6.3.14 Ypsomed AG
    • 6.3.15 OK Biotech Co. Ltd.
    • 6.3.16 SD Biosensor Inc.
    • 6.3.17 Sinocare Inc.
    • 6.3.18 B. Braun Melsungen AG
    • 6.3.19 A. Menarini Diagnostics (GlucoMen)
    • 6.3.20 Beurer GmbH

7. Market Opportunities & Future Outlook

  • 7.1 White-space & Unmet-need Assessment
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Global Self-Monitoring Blood Glucose Market Report Scope

Self-monitoring blood glucose (SMBG) is an important aid in diabetes mellitus care. Patients with diabetes can measure their blood glucose to detect hypoglycemia, adjust the insulin doses as needed, and establish the response to nutrition and pharmacotherapy. 

The Self-monitoring Blood Glucose Market is segmented into Components (Glucometer Devices, Test Strips, and Lancets) and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America). The report offers the value (in USD) and volume (in Units) for the above segments.

By Product Type Glucose Meters
Test Strips
Lancets
By Technology Electrochemical
Photometric
By Modality Hand-held Conventional
Wearable / Connected
By Application Type 1 Diabetes
Type 2 Diabetes
Gestational Diabetes
Prediabetes
By End-user Hospitals & Clinics
Home-care Settings
Diagnostic Laboratories
Ambulatory Surgical Centers
By Distribution Channel Retail Pharmacies
Hospital Pharmacies
Online Pharmacies
Others
Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
By Product Type
Glucose Meters
Test Strips
Lancets
By Technology
Electrochemical
Photometric
By Modality
Hand-held Conventional
Wearable / Connected
By Application
Type 1 Diabetes
Type 2 Diabetes
Gestational Diabetes
Prediabetes
By End-user
Hospitals & Clinics
Home-care Settings
Diagnostic Laboratories
Ambulatory Surgical Centers
By Distribution Channel
Retail Pharmacies
Hospital Pharmacies
Online Pharmacies
Others
Geography
North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Key Questions Answered in the Report

How large is the Self-Monitoring Blood Glucose market in 2025?

The Self-Monitoring Blood Glucose market size is USD 15.47 billion in 2025, with a 6.23% CAGR outlook to 2030.

Which product type generates the most revenue?

Test strips dominate, holding 76.7% of 2024 revenue thanks to high daily consumption.

What region is growing fastest through 2030?

Asia-Pacific posts the highest 9.5% CAGR, driven by rising diabetes prevalence and broader insurance access.

How are connected devices impacting adoption?

Bluetooth-enabled meters upload readings to apps, driving a 13.85% CAGR in the wearable/connected modality segment and improving patient engagement.

What sustainability steps are manufacturers taking?

Firms are introducing recyclable strip vials, bioplastic components, and programs such as Novo Nordisk’s ReMed take-back initiative to cut device waste.

Why are price pressures acute in test strips?

Generic alternatives and pharmacy private labels have pushed selling prices down 5-7% annually in mature markets, compelling differentiation through digital features and services.

Page last updated on:

Self-Monitoring Blood Glucose Market Report Snapshots